Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

CD Private Equity Fund III (CD3.AX)

Compare
1.1300
+0.0100
+(0.89%)
At close: April 4 at 12:12:57 PM GMT+11
Loading Chart for CD3.AX
  • Previous Close 1.1200
  • Open 1.1300
  • Bid 1.1300 x --
  • Ask 1.1550 x --
  • Day's Range 1.1300 - 1.1300
  • 52 Week Range 1.1200 - 1.5200
  • Volume 9,570
  • Avg. Volume 23,449
  • Market Cap (intraday) 81.392M
  • Beta (5Y Monthly) 0.66
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date May 28, 2025 - Jun 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jan 29, 2024
  • 1y Target Est --

CD Private Equity Fund III specializes in investments in small and specialised private equity funds targeting lower middle-market operating businesses in the United States.

www.cdfunds.com.au/fund3/

--

Full Time Employees

--

Fiscal Year Ends

Recent News: CD3.AX

View More

Performance Overview: CD3.AX

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

CD3.AX
1.92%
S&P/ASX 200 [XJO] (^AXJO)
6.02%

1-Year Return

CD3.AX
9.95%
S&P/ASX 200 [XJO] (^AXJO)
1.36%

3-Year Return

CD3.AX
59.20%
S&P/ASX 200 [XJO] (^AXJO)
2.05%

5-Year Return

CD3.AX
433.15%
S&P/ASX 200 [XJO] (^AXJO)
51.31%

Compare To: CD3.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CD3.AX

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    81.39M

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.65

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    87.74%

  • Return on Assets (ttm)

    0.62%

  • Return on Equity (ttm)

    1.57%

  • Revenue (ttm)

    2.56M

  • Net Income Avi to Common (ttm)

    2.24M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.19M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.68M

Research Analysis: CD3.AX

View More

Company Insights: CD3.AX

Research Reports: CD3.AX

View More

People Also Watch